Author

J. J. N. Goh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Approach:statistical model· 2 Assay:clinical cohort / trial· 1 Organism:human· 1

Frequent Co-Authors

E. Nuermberger· 2 shared N. Zhang· 2 shared Q. Wang· 2 shared R. M. Savic· 2 shared A. Deitchman· 1 shared J. P. Ernest· 1 shared N. Strydom· 1 shared R. C. van Wijk· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

E. Nuermberger

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacology & ToxicologybioRxivPreprintFeb 16, 2023

Prospectively predicting BPaMZ Phase IIb outcomes using a translational preclinical mouse to human platform

Q. Wang, J. J. N. Goh, N. Zhang…·R. M. Savic

This paper predicts outcomes of BPaMZ tuberculosis treatment regimens using a translational preclinical mouse to human platform, showing potential to shorten treatment duration and prevent relapse.

DOI 10.1101/2023.02.16.528876

mousehuman

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivJan 18, 2023

Translational predictions of phase 2a first-in patient efficacy studies for antituberculosis drugs

R. M. Savic, J. J. N. Goh, J. P. Ernest…·E. Nuermberger

The paper predicts clinical efficacy of antituberculosis drugs using preclinical PKPD data and translational pharmacology models to reduce phase 2a trial costs and failures.

DOI 10.1183/13993003.00165-2023

mousestatistical model

𝕏 PostBluesky